Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
A research published this week in the Journal of Behavioral and Brain Science (JBBS) shows that the nutraceutical Endorphinate is a clinically effective and safe treatment for chronic emotional and physical distress, including anxiety, anger, depression, cravings, and pain hypersensitivity.
Endorphinate is developed by a team of scientists associated with mind-body healing pioneer and endocrinologist Dr Deepak Chopra, and world-renowned neurologist and Alzheimer’s researcher Dr Rudolph Tanzi. It is a scientific formulation of health-promoting plant extracts and amino acids that has a direct effect on endorphins, which are natural brain chemicals that create a sense of calm, pleasure, and wellbeing.
Endorphinate combines specific agents that increase the release of endorphins with agents that switch endorphin receptors from an excitatory (distress/pain) to an inhibitory (calm/comfort) mode.
As the peer-reviewed study published in JBBS describes, a team of scientists led by Dr Stanley M. Crain, Professor Emeritus, Dept. of Neuroscience, Albert Einstein College of Medicine, and Dr Steven Crain, neuropsychotherapist carried out a 26-month study to assess the benefits of Endorphinate for individuals suffering from moderate-to-severe emotional and/or physical distress.
The study found that Endorphinate provided strong clinical benefits, including reduced anxiety, anger, depressed mood, pain hypersensitivity, and cravings. Most participants reported greater calm, comfort, well-being, and pleasure as well as increased mental clarity, energy, productivity, healthier lifestyle choices, and an adaptive response to life’s stresses.
The nutraceutical is produced and distributed worldwide by Pondera Pharmaceuticals, Inc.